by telrheum | Sep 29, 2024 | Ankylosing Spondylitis, Biologic Therapy, Spondyloarthritis
The study explored the long-term safety and effectiveness of Bimekizumab (BKZ), a monoclonal antibody designed to block two proteins involved in inflammation, IL-17A and IL-17F. This dual inhibition helps control the excessive inflammation seen in ankylosing...
by telrheum | Sep 28, 2024 | Spondyloarthritis, Acute Phase Reactants, Ankylosing Spondylitis, C-reactive Protein, JAK Inhibitor, Tofacitinib
This article presents a post hoc analysis of how baseline (BL) C-Reactive Protein (CRP) levels affect the efficacy and safety of Tofacitinib, a medication used to treat Ankylosing Spondylitis (AS). Tofacitinib is a Janus kinase inhibitor, a type of drug that helps...
